Get to know our clinical trials
Clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of YL201 as a single drug and in combination with other anticancer treatments in patients with advanced solid tumors
THE MAIN GOAL OF THIS STUDY IS TO EXAMINE YL201 IN MONOTHERAPY (PART 2 PARTICIPANTS) OR IN COMBINATION WITH ATEZOLIZUMAB (PART 3 PARTICIPANTS) AT DIFFERENT DOSES, TO FIND OUT IF THE STUDY TREATMENT IS SAFE, TO UNDERSTAND HOW THE BODY PROCESSES THE STUDY TREATMENT, AND TO UNDERSTAND WHAT THE STUDY TREATMENT DOES TO THE BODY AND ITS CANCER.
Technical Summary
- FIRST-IN-HUMAN, MULTICENTER, OPEN-LABEL, PHASE IA/IB STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF YL201 AS A SINGLE DRUG AND IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: 2024-517589-41-00
- Protocol number: YL201-INT-101-01
- Promoter: MediLink Therapeutics (Suzhou) Co., Ltd
- Molecule/Drug: YL201
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.